• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统评价局部晚期非小细胞肺癌患者的健康相关生活质量:是否已达到现状?

Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?

机构信息

Department of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium.

Department of Respiratory Medicine, Ghent University Hospital and Ghent University, Ghent, Belgium.

出版信息

Crit Rev Oncol Hematol. 2017 Nov;119:40-49. doi: 10.1016/j.critrevonc.2017.09.014. Epub 2017 Sep 28.

DOI:10.1016/j.critrevonc.2017.09.014
PMID:29065984
Abstract

Lung cancer and its treatment have an important impact on the patients' health-related quality-of-life (HRQoL). A systematic literature review of prospective clinical studies published since 2005 and measuring HRQoL in patients with locally-advanced non-small cell lung cancer (LA- NSCLC) was performed. Besides reviewing the HRQoL impact of LA-NSCLC treatment, it critically examined the frequency, methodology and quality of HRQoL data collection and analysis in LA-NSCLC clinical studies. Out of 814 potentially eligible publications, only 27 (representing 19 individual studies) met the inclusion criteria. Eight studies documented an impact on HRQoL. Large variability in use of HRQoL instruments, statistical analysis and methodological quality was observed. Reporting of HRQoL data lacks standardization, but recent initiatives establishing recommendations to standardize the analysis and reporting of HRQoL in cancer trials are expected to address these issues. Overall, more research is needed to evaluate the treatment impact on HRQoL in both clinical trials and daily care.

摘要

肺癌及其治疗对患者的健康相关生活质量(HRQoL)有重要影响。对 2005 年以来发表的前瞻性临床研究进行了系统的文献回顾,以测量局部晚期非小细胞肺癌(LA-NSCLC)患者的 HRQoL。除了审查 LA-NSCLC 治疗对 HRQoL 的影响外,还对 LA-NSCLC 临床研究中 HRQoL 数据收集和分析的频率、方法和质量进行了批判性评估。在 814 篇潜在合格的出版物中,只有 27 篇(代表 19 项单独的研究)符合纳入标准。有 8 项研究记录了对 HRQoL 的影响。观察到 HRQoL 工具的使用、统计分析和方法学质量存在很大差异。HRQoL 数据的报告缺乏标准化,但预计最近的一些举措将建立癌症试验中 HRQoL 分析和报告的标准化建议来解决这些问题。总体而言,需要更多的研究来评估临床试验和日常护理中治疗对 HRQoL 的影响。

相似文献

1
Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?系统评价局部晚期非小细胞肺癌患者的健康相关生活质量:是否已达到现状?
Crit Rev Oncol Hematol. 2017 Nov;119:40-49. doi: 10.1016/j.critrevonc.2017.09.014. Epub 2017 Sep 28.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials.非小细胞肺癌患者与健康相关的生活质量:随机对照试验中的方法学问题
J Clin Oncol. 2003 Aug 1;21(15):2982-92. doi: 10.1200/JCO.2003.01.203.
4
Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: A systematic review.评估一线非小细胞肺癌临床试验中生活质量分析的方法学质量:系统评价。
Crit Rev Oncol Hematol. 2022 Aug;176:103747. doi: 10.1016/j.critrevonc.2022.103747. Epub 2022 Jun 16.
5
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶(<I>ALK</I>)重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
6
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法(不包括检查点抑制剂)。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
7
Anti-IL5 therapies for asthma.用于哮喘的抗白细胞介素-5疗法。
Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3.
8
Gefitinib for advanced non-small cell lung cancer.吉非替尼用于治疗晚期非小细胞肺癌。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2.
9
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.促红细胞生成素α、促红细胞生成素β和达比加群酯治疗癌症相关性贫血(尤其是癌症治疗所致贫血)的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130.
10
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.

引用本文的文献

1
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.非小细胞肺癌患者治疗前症状、急性和迟发性毒性与患者报告的健康相关生活质量的相关性:REQUITE 研究结果。
Radiother Oncol. 2022 Nov;176:127-137. doi: 10.1016/j.radonc.2022.09.020. Epub 2022 Oct 3.
2
Commentary: When does the burden of treatment outweigh the biological benefit?评论:治疗负担何时会超过生物学益处?
JTCVS Open. 2020 Sep 30;4:105-106. doi: 10.1016/j.xjon.2020.08.018. eCollection 2020 Dec.
3
Understanding the lived experience of lung cancer: a European social media listening study.
理解肺癌患者的生存体验:一项欧洲社交媒体聆听研究。
BMC Cancer. 2022 Apr 30;22(1):475. doi: 10.1186/s12885-022-09505-4.
4
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).真实环境下接受根治性放疗的非小细胞肺癌患者的健康相关生活质量和毒性概述(REQUITE 研究)。
Lung Cancer. 2022 Apr;166:228-241. doi: 10.1016/j.lungcan.2022.03.010. Epub 2022 Mar 15.
5
Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study.肺癌患者自我报告结局与神经认知功能的真实世界数据:PRO-Long研究
Front Oncol. 2021 Jun 17;11:685605. doi: 10.3389/fonc.2021.685605. eCollection 2021.
6
Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review.晚期非小细胞肺癌患者的健康相关生活质量:基于系统文献综述的方法学评估
Front Oncol. 2019 Aug 12;9:715. doi: 10.3389/fonc.2019.00715. eCollection 2019.
7
The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden.欧洲晚期非小细胞肺癌(NSCLC)的人文负担:一项将患者临床因素与患者和照护者负担联系起来的真实世界调查。
Qual Life Res. 2019 Jul;28(7):1849-1861. doi: 10.1007/s11136-019-02152-6. Epub 2019 Mar 2.
8
Frequency and Prognostic Impact of Consistently Low Edmonton Symptom Assessment System Score in the Patients Treated with Palliative Radiotherapy.姑息性放疗患者中埃德蒙顿症状评估系统评分持续较低的频率及其预后影响
Cureus. 2018 Jan 6;10(1):e2032. doi: 10.7759/cureus.2032.